The Importance of Quality of Life in Relapsed CLL

Zana Brutinib was shown to have an improved superior overall response rate in the Alpine study. And what raised everyone's eyebrows about a year and a half ago was that there was an interim analysis done showing a potential improved progression-free survival. Now this has now been confirmed at this two-year follow-up. This seems to improve in the high-risk patients of Dell 17P, where we're seeing a 77.6% PFS at two years with Zana BrutInib compared to 55% with iburinib. The other thing that we see here is Calabrutinib having a statistically significantly benefit towards AFib. We saw six fatal cardiac events